Heparin-induced thrombocytopenia resident survival guide: Difference between revisions
No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
Line 10: | Line 10: | ||
* HITT: Heparin induced thrombocytponia with thrombosis | * HITT: Heparin induced thrombocytponia with thrombosis | ||
* Isolated HIT: Heparin induced thrombocytponia without evidence of thrombosis<ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=PMC3278058 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270 }} </ref> | * Isolated HIT: Heparin induced thrombocytponia without evidence of thrombosis<ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=PMC3278058 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270 }} </ref> | ||
*Subacute HIT: Platelet level is back to normal following HIT; however, HIT antibodies are still positive | |||
==Causes== | ==Causes== | ||
Line 63: | Line 64: | ||
{{familytree | | | | |!| | | | | | | | | | | }} | {{familytree | | | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | A01 | | | | | | | | | | A01= <div style="height: 1em; width: 25em; padding:1em;">'''Suspicion of HIT'''</div>}} | {{familytree | | | | A01 | | | | | | | | | | A01= <div style="height: 1em; width: 25em; padding:1em;">'''Suspicion of HIT'''</div>}} | ||
{{familytree | |,|-|-|^|-|-|.| | | | | | | | }} | {{familytree | |,|-|-|^|-|-|.| | | | | | | | }} | ||
{{familytree | B01 | | | | B02 | | | | | | | B01= '''Low clinical probability'''| B02= '''Intermediate/high clinical probability'''}} | {{familytree | B01 | | | | B02 | | | | | | | B01= '''Low clinical probability'''| B02= '''Intermediate/high clinical probability'''}} | ||
{{familytree | |!| | | | | |!| | | | | | | | }} | {{familytree | |!| | | | | |!| | | | | | | | }} | ||
{{familytree | C01 | | | | C02 | | | | | | | C01='''Unlikely HIT''' <br><div style="float: left; text-align: left">❑ Consider alternative diagnoses <br>❑ Continue heparin </div>| C02=<div style="float: left; text-align: left">❑ Discontinue heparin <br>❑ Begin alternative anticoagulation</div>}} | {{familytree | C01 | | | | C02 | | | | | | | C01='''Unlikely HIT''' <br><div style="float: left; text-align: left">❑ Consider alternative diagnoses <br>❑ Continue heparin </div>| C02=<div style="float: left; text-align: left">❑ Discontinue heparin <br>❑ Begin alternative anticoagulation</div>}} | ||
{{familytree | | | | | | | |!| | | | | | | | }} | {{familytree | | | | | | | |!| | | | | | | | }} | ||
{{familytree | | | | | | | D01 | | | | | | | D01=❑ Order anti PF4 antibodies}} | {{familytree | | | | | | | D01 | | | | | | | D01=❑ Order anti PF4 antibodies}} | ||
{{familytree | |,|-|-|-|v|-|^|-|v|-|-|-|.| | }} | {{familytree | |,|-|-|-|v|-|^|-|v|-|-|-|.| | }} | ||
{{familytree | E01 | | E02 | | E03 | | E04 | E01= Moderately/strongly positive test| E02= Weakly positive test<br> PLUS<br> High clinical probability| E03= Weakly positive test <br> PLUS <br> Intermediatre clinical probability| E04=Negative}} | {{familytree | E01 | | E02 | | E03 | | E04 | E01= Moderately/strongly positive test| E02= Weakly positive test<br> PLUS<br> High clinical probability| E03= Weakly positive test <br> PLUS <br> Intermediatre clinical probability| E04=Negative}} | ||
{{familytree | | |!| |!| | | | | |!| |!| | | }} | {{familytree | | |!| |!| | | | | |!| |!| | | }} | ||
{{familytree | | | F01 | | | | | | F02 | | | F01=❑ Order functional assay| F02= '''Unlikely HIT''' <br><div style="float: left; text-align: left">❑ Consider alternative diagnoses <br>❑ Continue heparin</div>}} | {{familytree | | | F01 | | | | | | F02 | | | F01=❑ Order functional assay| F02= '''Unlikely HIT''' <br><div style="float: left; text-align: left">❑ Consider alternative diagnoses <br>❑ Continue heparin</div>}} | ||
{{familytree | |,|-|^|-|.| | | | | | | | | | }} | {{familytree | |,|-|^|-|.| | | | | | | | | | }} | ||
{{familytree | G01 | | G02 | | | | | | | | | G01= '''Positive test'''<br> Likely HIT| G02= '''Negative test''' <br> HIT undetermined}} | {{familytree | G01 | | G02 | | | | | | | | | G01= '''Positive test'''<br> Likely HIT| G02= '''Negative test''' <br> HIT undetermined}} | ||
{{familytree/end}} | {{familytree/end}} | ||
<br> | <br> | ||
Line 114: | Line 115: | ||
| '''[[PCI]]'''|| Use [[bivalirudin]] or [[argatraban]] ||Use [[bivalirudin]] or [[argatraban]] | | '''[[PCI]]'''|| Use [[bivalirudin]] or [[argatraban]] ||Use [[bivalirudin]] or [[argatraban]] | ||
|- | |- | ||
| '''[[Dialysis|Renal replacement therapy]]'''||Use [[argatroban]] or [[ | | '''[[Dialysis|Renal replacement therapy]]'''||Use [[argatroban]] or [[danaparoid]] || Use regional citrate | ||
|- | |- | ||
| '''[[Pregnancy]]''' ||Use [[ | | '''[[Pregnancy]]''' ||Use [[danaparoid]]|| - | ||
|- | |- | ||
|} | |} |
Revision as of 16:17, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Rim Halaby, M.D. [2]
Definition
Heparin induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that predisposes to elevated risks of arterial and venous thromboembolism.
- Typical-onset HIT: within 5 to 10 days following the initiation of heparin
- Early-onset HIT: within 24 hours following the initiation of heparin
- Delayed-onset HIT: up to 3 weeks following the cessation of heparin[1]
- HITT: Heparin induced thrombocytponia with thrombosis
- Isolated HIT: Heparin induced thrombocytponia without evidence of thrombosis[1]
- Subacute HIT: Platelet level is back to normal following HIT; however, HIT antibodies are still positive
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Screening for HIT
❑ Asses the risk of HIT | |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
Risk <1% | Risk >1% | ||||||||||||||||||||||||||||||||||||||
❑ Do not monitor platelet count | ❑ Monitor platelet count every 2 or 3 days from day 4 to day 14 (or until heparin is stopped) | ||||||||||||||||||||||||||||||||||||||
Algorithm based on the 2012 ACCP evidence based clinical practice guidelines.[1]
Diagnostic Approach to HIT
Thrombocytopenia ❑ Platelet count <150,000/mm3, OR ❑ >30-50% decrease decrease of platelet from baseline ❑ Recent heparin or LMWH use in the previous 5- 14 days | |||||||||||||||||||||||||||||||
Characterize the symptoms (if present): ❑ Arterial thromboembolism ❑ Venous thromboembolism ❑ Unusual manifestations: - Skin necrosis at SC heparin injection sites | |||||||||||||||||||||||||||||||
Consider alternative diagnoses: ❑ Infection ❑ Medications other than heparin ❑ DIC ❑ Hemodilution ❑ Intravascular devices ❑ Extracorporeal circuits | |||||||||||||||||||||||||||||||
Suspicion of HIT | |||||||||||||||||||||||||||||||
Low clinical probability | Intermediate/high clinical probability | ||||||||||||||||||||||||||||||
Unlikely HIT ❑ Consider alternative diagnoses ❑ Continue heparin | ❑ Discontinue heparin ❑ Begin alternative anticoagulation | ||||||||||||||||||||||||||||||
❑ Order anti PF4 antibodies | |||||||||||||||||||||||||||||||
Moderately/strongly positive test | Weakly positive test PLUS High clinical probability | Weakly positive test PLUS Intermediatre clinical probability | Negative | ||||||||||||||||||||||||||||
❑ Order functional assay | Unlikely HIT ❑ Consider alternative diagnoses ❑ Continue heparin | ||||||||||||||||||||||||||||||
Positive test Likely HIT | Negative test HIT undetermined | ||||||||||||||||||||||||||||||
The most studied functional assays are serotonin release assay (SRA) and Heparin induced platelet activation assay (HIPA).[2]
The diagnostic algorithm is based on "How I treat heparin-induced thrombocytopenia" from Blood (2012).[2]
Treatment of HIT
High suspicion or confirmed HIT | |||||||||||||||||||
HIT with thrombosis | Isolated HIT | ||||||||||||||||||
❑ Perform a lower extremity U/S to R/O asymptomatic DVT[2] | |||||||||||||||||||
Presence of asymptomatic DVT | No DVT | ||||||||||||||||||
❑ Discontinue heparin ❑ Initiate non heparin anticoagulation for 3-6 months: - Argatroban (can be used in renal insufficiency) - Lepirudin - Danaparoid[2] | ❑ Discontinue heparin ❑ Initiate non heparin anticoagulation until platelets are back to normal:[2] - Argatroban (can be used in renal insufficiency) - Lepirudin - Danaparoid | ||||||||||||||||||
❑ Check if patient is/needs to be on VKA | |||||||||||||||||||
❑ Don't start VKA until the platelet count goes back to normal, after which initiate VKA at low doses ❑ When VKA is to be started, overlap it with non heparin anticoagulant for at least 5 days until INR is within the target range ❑ If VKAis started when patient is diagnosed with HIT, administer vitamin K[1] | |||||||||||||||||||
Special Considerations
Shown below is a table summarizing the appropriate choice of anticoagulation therapy in special situations.[1]
Special situations | Acute HIT or subacute HIT (normal platelets and positive antibodies) | Past medical history of HIT |
Cardiac surgery | Urgent cardiac surgery: Use bivalirudin Non urgent cardiac surgery: Delay the surgery until HIT has resolved and antibodies are negative |
Negative antibodies: Use heparin (short term) Positive antibodies: Use bivalirudin |
PCI | Use bivalirudin or argatraban | Use bivalirudin or argatraban |
Renal replacement therapy | Use argatroban or danaparoid | Use regional citrate |
Pregnancy | Use danaparoid | - |
Do's
- In case of severe thrombocytopenia among patients with HIT, administer platelet transfusions when the patient is bleeding or when performing procedures associated with an elevated risk of bleeding.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S; et al. (2012). "Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e495S–530S. doi:10.1378/chest.11-2303. PMC 3278058. PMID 22315270.
- ↑ 2.0 2.1 2.2 2.3 2.4 Cuker A, Cines DB (2012). "How I treat heparin-induced thrombocytopenia". Blood. 119 (10): 2209–18. doi:10.1182/blood-2011-11-376293. PMID 22246036.